ClinicalTrials.Veeva

Menu

Healthcare Cost and Resource Utilization Related to Metastatic Renal Cell Carcinoma Treatment With Intravenous and Oral Agents

Bristol-Myers Squibb (BMS) logo

Bristol-Myers Squibb (BMS)

Status

Withdrawn

Conditions

Renal Cell Carcinoma

Treatments

Other: Non-Interventional

Study type

Observational

Funder types

Industry

Identifiers

NCT02928263
CA209-780

Details and patient eligibility

About

A retrospective study to evaluate healthcare cost and resource utilization for patients with metastatic renal cell carcinoma who have been treated with IV or oral agents

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Diagnosis with metastatic renal cell carcinoma
  • Prescription/administration of one of the IV or oral agents examined in the study

Exclusion criteria

  • Patients with other primary cancer diagnosis before RCC diagnosis
  • Patients with pregnancy or HIV/AIDS

Trial design

0 participants in 2 patient groups

Patients treated with IV agents
Description:
Metastatic renal cell carcinoma patients treated with IV agents
Treatment:
Other: Non-Interventional
Patients treated with oral agents
Description:
Metastatic renal cell carcinoma patients treated with oral agents
Treatment:
Other: Non-Interventional

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems